Intraperitoneal CAR T cells for peritoneal mesothelioma
Official title: Intraperitoneal CAR T-cell therapy for peritoneal mesothelioma
Funded at Sloan-Kettering Inst Can Research · NIH-11443990 · Data updated 2026-11-12
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $650,000 |
| NIH project number | 1R01FD008780-01 |
| Project ID | NIH-11443990 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with malignant peritoneal mesothelioma who are not eligible for extensive surgery and who have disease confined to the peritoneal cavity.
✕Less likely to help
Patients with widespread distant metastasis or those unable to tolerate any cellular therapy may not benefit.
What this research studies
This project focuses on patients with malignant peritoneal mesothelioma, a rare cancer with very limited survival. It builds on prior work delivering mesothelin-targeted CAR T cells directly into the peritoneal cavity to enhance anti-tumor immune responses. The study will explore a CAR T-cell product with a PD-1 dominant negative receptor to improve persistence and activity while aiming to minimize systemic toxicity. Patients may receive intraperitoneal CAR T cells as part of a regional therapy approach rather than standard systemic treatment.
Why it matters
Potential benefit: If successful, patients could experience longer survival and better disease control with a regional therapy that minimizes off-target effects.
How similar studies have gone: Prior regional delivery of MSLN-targeted CAR T cells has shown safety and signals of efficacy in pleural mesothelioma and related cancers.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Adusumilli, Prasad S. — Sloan-Kettering Inst Can Research
- Study coordinator: Adusumilli, Prasad S.
Related research
Other NIH-funded projects on the same topics.
-
National Mesothelioma Biobank expands patient biospecimen and data sharing for research
A national biobank collects blood, tissue, and clinical data from mesothelioma patients to help researchers develop better diagnostics and treatments.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.